

# ZOGENIX

## Zogenix to Present at the Oppenheimer 24th Annual Healthcare Conference

December 4, 2013

SAN DIEGO, Dec. 4, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and pain, today announced that Ann Rhoads, Chief Financial Officer will present at the Oppenheimer 24<sup>th</sup> Annual Healthcare Conference in New York on December 11, 2013.

**Event:** Oppenheimer 24<sup>th</sup> Annual Healthcare Conference

**Date:** Wednesday, December 11, 2013

**Place:** New York City

**Time:** 8:55 am ET/ 5:55 am PT

The presentation will be webcast live and archived for 30 days on Zogenix' Investor Relations website at [ir.zogenix.com](http://ir.zogenix.com).

### About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company committed to developing and commercializing therapies that address specific clinical needs for people living with CNS and pain-related conditions who need innovative treatment alternatives to help them return to normal daily functioning. Zogenix recently received FDA approval for Zohydro ER (hydrocodone bitartrate) extended-release capsules, the first extended-release oral formulation of hydrocodone without acetaminophen. Zogenix developed and commercialized the first needle-free subcutaneous injection, SUMAVEL® DosePro® (sumatriptan injection) for migraine and cluster headache. The development pipeline for Zogenix includes a once-monthly subcutaneous injection for schizophrenia.

FPR

### CONTACT: INVESTORS:

Zack Kubow | The Ruth Group  
646.536.7020 | [zkubow@theruthgroup.com](mailto:zkubow@theruthgroup.com)

### MEDIA:

Amy Wheeler | The Ruth Group  
646.536.7025 | [awheeler@theruthgroup.com](mailto:awheeler@theruthgroup.com)

Zogenix